Nuveen
DNLI icon

Nuveen’s Denali Therapeutics DNLI Stock Holding History

Nuveen’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
608,967
+313,381
+106% +$6.44M ﹤0.01% 1415
2026
Q1 		$5.68M Buy
295,586
+20,078
+7% +$399K ﹤0.01% 1828
2025
Q4 		$4.55M Sell
275,508
-9,269
-3% -$156K ﹤0.01% 1953
2025
Q3 		$4.13M Sell
284,777
-310,440
-52% -$4.46M ﹤0.01% 1993
2025
Q2 		$8.33M Buy
595,217
+272,272
+84% +$3.83M ﹤0.01% 1623
2025
Q1 		$4.39M Sell
322,945
-32,112
-9% -$615K ﹤0.01% 1994
2024
Q4 		$7.24M Sell
355,057
-360,243
-50% -$9.22M ﹤0.01% 1785
2024
Q3 		$20.8M Sell
715,300
-358,557
-33% -$8.89M 0.01% 1165
2024
Q2 		$24.9M Buy
1,073,857
+565,661
+111% +$10.9M 0.01% 987
2024
Q1 		$10.4M Buy
508,196
+188,759
+59% +$3.55M ﹤0.01% 1561
2023
Q4 		$6.86M Sell
319,437
-44,228
-12% -$876K ﹤0.01% 1798
2023
Q3 		$7.5M Sell
363,665
-1,791
-0.5% -$45.4K ﹤0.01% 1644
2023
Q2 		$10.8M Buy
365,456
+4,820
+1% +$136K ﹤0.01% 1475
2023
Q1 		$8.31M Sell
360,636
-15,111
-4% -$416K ﹤0.01% 1602
2022
Q4 		$10.4M Buy
375,747
+24,288
+7% +$723K ﹤0.01% 1460
2022
Q3 		$10.8M Sell
351,459
-8,699
-2% -$283K ﹤0.01% 1428
2022
Q2 		$10.6M Sell
360,158
-10,071
-3% -$264K ﹤0.01% 1467
2022
Q1 		$12.3M Sell
370,229
-6,815
-2% -$235K ﹤0.01% 1514
2021
Q4 		$16.8M Buy
377,044
+11,966
+3% +$567K 0.01% 1333
2021
Q3 		$19.3M Sell
365,078
-18,982
-5% -$1.07M 0.01% 1297
2021
Q2 		$30.1M Buy
384,060
+106,439
+38% +$6.58M 0.01% 1069
2021
Q1 		$15.9M Sell
277,621
-14,241
-5% -$953K 0.01% 1490
2020
Q4 		$24.4M Sell
291,862
-36,489
-11% -$2.21M 0.01% 1121
2020
Q3 		$11.8M Sell
328,351
-1,328
-0.4% -$40K ﹤0.01% 1416
2020
Q2 		$7.97M Buy
329,679
+46,241
+16% +$1.09M ﹤0.01% 1641
2020
Q1 		$4.96M Buy
283,438
+103,045
+57% +$2.15M ﹤0.01% 1720
2019
Q4 		$3.14M Buy
180,393
+1,163
+0.6% +$19.4K ﹤0.01% 2233
2019
Q3 		$2.75M Buy
179,230
+4,255
+2% +$81.3K ﹤0.01% 2256
2019
Q2 		$3.63M Buy
+174,975
New +$3.92M ﹤0.01% 2155

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's DNLI Position: Q2 2026 in Review

Nuveen increased its Denali Therapeutics (DNLI) stake by 106% in Q2 2026, buying an estimated $6.44M and bringing the position to 608,967 shares worth $15.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1415.

Nuveen first reported a position in DNLI in Q2 2019 and has held it in 29 quarters since. The position peaked at $30.1M in Q2 2021. 293 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Nuveen held 608,967 shares of Denali Therapeutics worth $15.7M as of Q2 2026.
  • Nuveen bought 313,381 Denali Therapeutics shares in Q2 2026, an estimated $6.44M.
  • Denali Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1415 holding.
  • Nuveen first reported a position in Denali Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Denali Therapeutics position peaked at $30.1M in Q2 2021.
  • 293 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.